pharma · Agitation · Agitation,Psychomotor · BTAI
BioXcel Therapeutics
BioXcel Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
- Founded
- 2017
- Employees
- 56
- Programs
- 17
- Drugs
- 9
- Patents
- 18
BioXcel Therapeutics projects
5 ClinicalTrials.gov programs sponsored by BioXcel Therapeutics.
BioXcel Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BXCL501 80 Micrograms
BioXcel Therapeutics
Schizophrenia
1 trial -
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
BioXcel Therapeutics
Alcohol Use Disorder (AUD)
1 trial -
Placebo
BioXcel Therapeutics
Alcohol Use Disorder (AUD)
1 trial -
Sublingual film containing BXCL501 (Dexmedetomidine)
BioXcel Therapeutics
Agitation
1 trial -
Talabostat Mesylate
BioXcel Therapeutics
Cancer of Pancreas
1 trial
Frequently asked questions
How many clinical projects does BioXcel Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.